Clearside Biomedical (NASDAQ:CLSD) Trading Up 2.7%
Clearside Biomedical Inc (NASDAQ:CLSD)’s stock price rose 2.7% during mid-day trading on Wednesday . The company traded as high as $0.74 and last traded at $0.76, approximately 12,836 shares traded hands during mid-day trading. A decline of 99% from the average daily volume of 1,805,372 shares. The stock had previously closed at $0.74.
Several equities analysts have commented on the stock. Wedbush reissued a “buy” rating and set a $4.00 target price on shares of Clearside Biomedical in a research report on Tuesday, August 6th. Needham & Company LLC cut Clearside Biomedical from a “buy” rating to a “hold” rating in a research report on Friday, August 9th. Zacks Investment Research upgraded Clearside Biomedical from a “hold” rating to a “strong-buy” rating and set a $1.50 price target for the company in a research note on Monday, August 12th. ValuEngine raised Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, JMP Securities set a $3.00 price objective on Clearside Biomedical and gave the company a “buy” rating in a research note on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Clearside Biomedical presently has a consensus rating of “Hold” and a consensus price target of $3.64.
The business’s 50 day moving average is $0.95 and its 200-day moving average is $1.16. The company has a debt-to-equity ratio of 0.69, a quick ratio of 3.47 and a current ratio of 3.47. The firm has a market capitalization of $25.49 million, a price-to-earnings ratio of -0.29 and a beta of -0.58.
Several institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its position in shares of Clearside Biomedical by 4.9% during the 4th quarter. Geode Capital Management LLC now owns 303,512 shares of the company’s stock worth $324,000 after purchasing an additional 14,181 shares during the last quarter. Deutsche Bank AG increased its position in Clearside Biomedical by 487.2% in the 4th quarter. Deutsche Bank AG now owns 536,761 shares of the company’s stock worth $573,000 after buying an additional 445,346 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Clearside Biomedical by 63.4% during the first quarter. SG Americas Securities LLC now owns 57,234 shares of the company’s stock worth $79,000 after buying an additional 22,213 shares during the last quarter. Parallel Advisors LLC acquired a new position in shares of Clearside Biomedical during the first quarter worth approximately $87,000. Finally, A.R.T. Advisors LLC acquired a new position in shares of Clearside Biomedical during the second quarter worth approximately $95,000. Institutional investors and hedge funds own 11.95% of the company’s stock.
Clearside Biomedical Company Profile (NASDAQ:CLSD)
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.
Featured Story: Stock Symbol
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.